Menu
Search
|

Menu

Close
X

YanAn Bicon Pharmaceutical Listed Co 002411.SZ (Shenzhen Stock Exchange)

19.89 CNY
-0.33 (-1.63%)
As of 2:00 AM EST
chart
Previous Close 20.22
Open 20.11
Volume 8,026,409
3m Avg Volume 11,186,440
Today’s High 20.66
Today’s Low 19.67
52 Week High 34.82
52 Week Low 15.19
Shares Outstanding (mil) 1,532.28
Market Capitalization (mil) 30,982.78
Forward P/E 35.43
Dividend (Yield %) 0.10 ( 0.49 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, CNY)
FY18
5,703
FY17
5,368
FY16
3,724
EPS (CNY)
FY18
0.393
FY17
0.583
FY16
0.673
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
35.43
36.27
Price to Sales (TTM)
vs sector
3.98
10.05
Price to Book (MRQ)
vs sector
3.28
4.56
Price to Cash Flow (TTM)
vs sector
--
26.55
Total Debt to Equity (MRQ)
vs sector
60.77
16.57
LT Debt to Equity (MRQ)
vs sector
30.82
13.04
Return on Investment (TTM)
vs sector
6.25
12.64
Return on Equity (TTM)
vs sector
9.58
13.67

EXECUTIVE LEADERSHIP

Xingfu Xiang
President, Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
Wen Dong
Finance Director, Since 2018
Salary: --
Bonus: --
Bing Chen
Vice President, Secretary of the Board, Since 2016
Salary: --
Bonus: --
Jun Guo
Vice President, Since 2016
Salary: --
Bonus: --
Yudong He
Vice President, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

North Building of Financial Bure
No.18, Zhongwu South Road, Xinyi
XUZHOU   JNG   221400

Phone: +86516.88602411
Site:

YanAn Bicon Pharmaceutical Listed Company, formerly JiangSu Bicon Pharmaceutical Listed Company, is a China-based company principally engaged in the research and development, manufacture and distribution of medical products, new energy materials and drug intermediates. The Company operates its businesses through three segments. The Pharmaceuticals segment provides circulatory system, digestive system, respiratory system, nervous system and ophthalmic products. The New Materials segment mainly consists of lithium hexafluorophosphate, high-strength and high modulus polyethylene fibers and others. The Pharmaceutical Intermediates segment consists of 7-ADCA, benzaldehyde, 5.5-dimethylhydantion and trichloropyridine. The Company distributes its products mainly in domestic market.

SPONSORED STORIES